



## IN THE UNITED STATES PATENT & TRADEMARK OFFICE

APPLICANT: Stephen Douglas Barrett, et al.

**EXAMINER:** 

RECEIVED

SERIAL NO.

: 10/031,149

**ART UNIT** 

FOU. FEB 2 8 2003

**FILED** 

: June 3, 2002

PAPER NO

-017 CENTER 1600/2900

**FOR** 

: METHOD FOR TREATING CHRONIC PAIN USING MEK INHIBITORS

## Statement as Provided by 37 CFR 1.97(b)

Commissioner for Patents Washington, D.C. 20231

Dear Sir:

The Applicants submit that a Supplemental Information Disclosure Statement submitted herewith is being filed within three months of the filing of a national application other than a continued prosecution application under 37 CFR 1.53(d); within three months of the date of entry of the national stage as set forth in 37 CFR 1.491 in an international application; before the mailing of the first Office Action on the merits, or before the mailing of a first Office Action after the filing of a request for continued examination under 37 CFR 1.114.

As such, the Applicants respectfully request consideration of the enclosed Supplemental Information Disclosure Statement and request that all references cited herein be printed on the face of the patent upon grant of the Application.

It is understood by the Applicants that this paper requires no fee; however, authorization is given to charge any necessary filing fees and any additional fees or credit any overpayment to Deposit Account 23-0455.

Respectfully submitted,

Dated: Telruary 17, 2003

Suzanne M. Harvey

Registration No. 42,640

Warner-Lambert Company LLC

2800 Plymouth Road Ann Arbor, MI 48105

Telephone: (734) 622-2658 Facsimile: (734) 622-2928

Approved for use through 09/30/2000. Of 19 064119.
Patent and Trademark Office: U.S. DEPARTMENT OF COMMERC Please type a plus sign (+) inside this box + Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it display valid OMB control number. 10/031,149 **Application Number TRANSMITTAL** June 3, 2002 **Filing Date FORM** Stephen Douglas Barrett, et al. **First Named Inventor Group Art Unit** 1614 (to be used for all correspondence after initial filing) **Examiner Name** A0000104-01-SMH Attorney Docket Number Total Number of Pages in This Submission **ENCLOSURES** (check all that apply) After Allowance Communication **Assignment Papers** Fee Transmittal Form to Group (for an Application) Appeal Communication to Board Fee Attached Drawing(s) of Appeals and Interferences Appeal Communication to Group Amendment / Response Licensing-related Papers (Appeal Notice, Brief, Reply Brief) Petition Routing Slip (PTO/SB/69) After Final **Proprietary Information** and Accompanying Petition Petition to Convert to a Affidavits/declaration(s) Status Letter Provisional Application Additional Enclosure(s) Power of Attorney, Revocation Extension of Time Request (please identify below) Change of Correspondence Address Supplemental Information **Terminal Disclaimer Express Abandonment Request** Disclosure Statement Statement as Provided by 37 CFR **Small Entity Statement** 1.97(b)Information Disclosure Statemen Return Postcard Request for Refund Certified Copy of Priority Document(s) Remarks Response to Missing Parts/ Incomplete Application Response to Missing Parts under 37 CFR 1.52 or 1.53 SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT Firm Individual name Suzanne M. Harvey Signature Date

## **CERTIFICATE OF MAILING**

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to: Assistant Commissioner for Patents, Washington, D.C. 20231 on this date: 20 2003

Typed or printed name Linda A. Zerby

Signature

Burden Hour Statement: This form is estimated to take 0.2 hoes to complete. Time will vary depending upon the needs of the individual case, Any comments on the amount of time you are required to complete this form should be send to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

Date

20,

Please type a plus sign (+) inside this box ->   +
--

PTO/SB/08B (08-00)

Approved for use through 10/31/2002. OMB 0651-0031

U. S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO

Sheet

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

> (use as many sheets as necessary) of 1 1

Compl t if Known				
Application Number 10/031149				
Filing Date	June 3, 2002			
First Named Inventor	Stephen Douglas Barrett, et al.			
Group Art Unit	1614			
Examiner Name				
Attorney Docket Number	A0000104-01-SMH			

		OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS	
Examiner Initials	Cite No.1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T²
		ALESSI, Dario R., et al., "PD 098059 Is a Specific Inhibitor of the Activation of Mitogen-activated Protein Kinase Kinase in Vitro and in Vivo", J. Biol. Chem., 1995, pp 27489-27494, Vol. 270, No. 46	
		HWANG, Daniel, et al., "Expression of Mitogen-Inducible Cyclooxygenase Induced by Lipopolysaccharide: Mediation through both mitogen-activated protein kinase and NF-KB signaling pathways in macrophages", Biochem Pharm, 1997, pp 87-96, Vol. 54, Issue 1	
		LARRIVEE, Jean-François, et al., "Role of the Mitogen-Activated Protein Kinases in the Expression of the Kinin B1 Receptors Induced by Tissue Injury ", J Immunol, 1998, pp 1419-1426, Vol. 160, No. 3	
		POLAKIEWICZ, Roberto D., et al., "A Mitogen-activated Protein Kinase Pathway Is Required for μ-Opioid Receptor Desensitization", J. Biol. Chem., 1998, pp 12402-12406. Vol. 273, No. 20	
		RECEIVE TECHCENTER 1600/2000	
		ECHO 28 2000	C
		LENTER 1600/201	
	ļ		

Examiner	Date	
Signature	Considered	

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U. S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

<sup>\*</sup>EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>&</sup>lt;sup>1</sup> Unique citation designation number. <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached.